Caris Life Sciences, Inc. (CAI) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $18.79, but acceptable to hold if already in. Reasons: Concentration risk — Product: MI Profile (84.4%); Earnings in 7 days (event risk).
Caris Life Sciences provides comprehensive molecular profiling and precision medicine solutions focused on oncology, with its MI Profile platform (whole exome and transcriptome sequencing) accounting for 84.4% of 2025 revenue from over 1,000,000 sequenced cases. The company... Read more
Hold if already holding. Not a fresh buy at $18.79, but acceptable to hold if already in. Reasons: Concentration risk — Product: MI Profile (84.4%); Earnings in 7 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 7d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductMI Profile84%10-K Item 1A: 'MI Profile, our tissue-based profiling solution, which accounted for 84.4% of our revenue for the year ended December 31, 2025'
Material Events(8-K, last 90d)
- 2026-04-02Item 1.01MEDIUMCaris entered $400M initial term loan plus $300M delayed draw credit facility with Blue Owl Capital and Blackstone as lenders, effective April 1, 2026. Unconditionally guaranteed by certain subsidiaries. No reason cited for prior credit arrangement termination.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $18.79, but acceptable to hold if already in. Reasons: Concentration risk — Product: MI Profile (84.4%); Earnings in 7 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $25.83 (+37.5%), stop $17.43 (−7.8%), A.R:R 3.4:1. Score 5.9/10, moderate confidence.
Take-profit target: $25.83 (+37.8% upside). Target $25.83 (+37.5%), stop $17.43 (−7.8%), A.R:R 3.4:1. Stop-loss: $17.43.
Concentration risk — Product: MI Profile (84.4%); Earnings in 7 days (event risk); Negative momentum.
Caris Life Sciences, Inc. trades at a P/E of N/A (forward 47.2). TrendMatrix value score: 6.7/10. Verdict: Hold.
14 analysts cover CAI with a consensus score of 4.3/5. Average price target: $30.
What does Caris Life Sciences, Inc. do?Caris Life Sciences provides comprehensive molecular profiling and precision medicine solutions focused on oncology,...
Caris Life Sciences provides comprehensive molecular profiling and precision medicine solutions focused on oncology, with its MI Profile platform (whole exome and transcriptome sequencing) accounting for 84.4% of 2025 revenue from over 1,000,000 sequenced cases. The company serves oncologists, biopharma partners, and academic centers; Caris Assure and Caris Detect blood-based solutions are under commercialization.